



PERMANENT ADMINISTRATIVE ORDER

BP 2-2026
CHAPTER 855
BOARD OF PHARMACY

FILED

01/23/2026 8:39 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocols, Standard Vaccination Protocols and Formulary: Devices & Supplies

EFFECTIVE DATE: 01/23/2026

AGENCY APPROVED DATE: 01/22/2026

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

RULES:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

RULE TITLE: Services: Prescribing - Formulary

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding Epinephrine to the Drug and Devices Formulary.

RULE TEXT:

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, an FDA-approved drug and device listed in the Formulary, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. Formulary devices and supplies:

- (1) Diabetic blood sugar testing supplies;
- (2) Injection supplies;
- (3) Nebulizers and associated supplies;
- (4) Inhalation spacers;
- (5) Peak flow meters;
- (6) International Normalized Ratio (INR) testing supplies;
- (7) Enteral nutrition supplies;
- (8) Ostomy products and supplies; and
- (9) Non-invasive blood pressure monitors; and
- (10) Continuous glucose monitors and associated supplies; and
- (11) Epinephrine.

STATUTORY/OTHER AUTHORITY: ORS 689.205

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

REPEAL: Temporary 855-115-0345 from BP 13-2025

RULE TITLE: Services: Prescribing Pursuant to - Protocol

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding new versions for HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, adopts Respiratory Syncytial Virus protocol v. 09/2025, amends current versions of the Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Adopts Managing Adverse Reactions protocol v. 08/2025. Repeals Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025) and Vaccination Protocol for Ages 6 months through 2 Years v. 08/13/2025.

RULE TEXT:

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

<https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>.

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024).

(2) Conditions Protocols:

(a) Cough and cold symptom management:

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) COVID-19 Antigen Self-Test (v. 12/2021);

(c) SARS-CoV-2 Antiviral (v. 08/2024).

(3) Preventative Care Protocols:

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 01/2026);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 01/2026);

(g) Contraception (v. 06/2025);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024); and

(4) Vaccine Protocols:

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 01/2026);

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 01/2026); and

(c) Vaccination Protocol for Managing Adverse Reactions (v. 08/2025).

(5) Board Excluded Vaccine Protocols:

(a) Coronavirus 19 (v. 01/2026);

(b) Influenza (v. 01/2026); and

(c) Respiratory Syncytial Virus (v. 09/2025).

[Publications: Publications referenced are available from the agency.]

STATUTORY/OTHER AUTHORITY: ORS 689.205, ORS 689.005

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005



PERMANENT ADMINISTRATIVE ORDER

BP 2-2026
CHAPTER 855
BOARD OF PHARMACY

FILED

01/23/2026 8:39 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocols, Standard Vaccination Protocols and Formulary: Devices & Supplies

EFFECTIVE DATE: 01/23/2026

AGENCY APPROVED DATE: 01/22/2026

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

RULES:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding Epinephrine to the Drug and Devices Formulary.

CHANGES TO RULE:

855-115-0340

Services: Prescribing - Formulary

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, an FDA-approved drug and device listed in the Formulary, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. Formulary devices and supplies:¶¶

- (1) Diabetic blood sugar testing supplies;¶¶
- (2) Injection supplies;¶¶
- (3) Nebulizers and associated supplies;¶¶
- (4) Inhalation spacers;¶¶
- (5) Peak flow meters;¶¶
- (6) International Normalized Ratio (INR) testing supplies;¶¶
- (7) Enteral nutrition supplies; ¶¶
- (8) Ostomy products and supplies; and¶¶
- (9) Non-invasive blood pressure monitors; and ¶¶
- (10) Continuous glucose monitors and associated supplies; and¶¶
- (11) Epinephrine.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

REPEAL: Temporary 855-115-0345 from BP 13-2025

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding new versions for HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, adopts Respiratory Syncytial Virus protocol v. 09/2025, amends current versions of the Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Adopts Managing Adverse Reactions protocol v. 08/2025. Repeals Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025) and Vaccination Protocol for Ages 6 months through 2 Years v. 08/13/2025.

CHANGES TO RULE:

855-115-0345

Services: Prescribing Pursuant to - Protocol

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

<https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>.

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024);

(2) Conditions Protocols:

(a) Cough and cold symptom management;

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) COVID-19 Antigen Self-Test (v. 12/2021);

(c) SARS-CoV-2 Antiviral (v. 08/2024);

(3) Preventative Care Protocols:

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);

(g) Contraception (v. 06/2025);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024); and

(4) Vaccine Protocols:

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 08/2025);

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 08/2025); and

(c) Vaccination Protocol for ~~Ages 3 through 6 Year~~ Managing Adverse Reactions (v. 08/2025);

~~(d).~~

~~(5) Board Excluded Vaccination Protocol for Ages 6 months through 2 Years;~~

~~(a) Coronavirus 19 (v. 01/2026);~~

~~(b) Influenza (v. 08/2025); and~~

~~(c) Vaccination Protocol for Managing Adverse Reaction~~ Respiratory Syncytial Virus (v. 08/2025);

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, ORS 689.005

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005